Project CARE: Cancer Risk Evaluation
Project CARE is a research study exploring a new way to assess your risk for hereditary cancer right from your primary care doctor's office. This study uses a "Relational Agent" (RA) named Alex, which is a chatbot integrated into a patient portal. Alex will provide education about hereditary cancer and help you complete questionnaires to evaluate your risk. The study aims to see how well this digital approach works and if it can help identify patients who might benefit from further genetic evaluation. You may be eligible if you are between 18 and 70 years old, speak English, and receive care at Rutgers Health primary care sites. The study will measure how many patients complete the risk assessment and how many are identified as high risk.
- Study design
- This interventional study plans to enroll 210 participants. It is exploring the use of a chatbot for cancer risk assessment.
- What's involved
- You will engage with the Relational Agent (chatbot) Alex through a patient portal to complete questionnaires about hereditary cancer risk.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track the proportion of patients identified as high risk through study completion, which is an average of 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Project CARE: CAncer Risk Evaluation
At a glance
Conditions
NCT07130487
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Rutgers, The State University of New Jersey
New Brunswick, New Jerseystudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Anita Y Kinney, PhD, RN · PRINCIPAL_INVESTIGATOR · Rutgers, The State University of New Jersey
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of Patients Completing the Hereditary Cancer Risk AssessmentUp to 3 months from enrollment
The proportion of patients who successfully complete the hereditary cancer risk assessment within the genetic care delivery portal. Completion is defined as receiving a final result statement, regardless of whether all assessment questions in the risk assessment module were answered.
- Proportion of Patients Identified as High RiskThrough study completion, an average of 12 months.
The percent of patients who completed the RA and are identified as high risk.